Billionaires Are Buying These High-Yield Dividend Stocks Left And Right. Should You Follow Their Lead? | Old North State Wealth News
Connect with us


Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?



Are you famous enough for picking great stocks to become a billionaire money manager? If not, then there’s a lot you could learn from the handful of folks who have.

It’s easier than ever for individuals to invest alongside the professionals. The U.S. Securities and Exchange Commission makes anyone with more than $100 million under management report their activity to the public every three months.

Image source: Getty Images.

The latest round of disclosures recently went live, and it seems dividend-paying healthcare stocks with high yields were on the minds of America’s wealthiest fund managers. Here’s a look at two dividend stocks that got lots of attention from billionaires lately to see if they could be right for your portfolio.

1. Pfizer

Shares of Pfizer (NYSE: PFE) are down by about half from a peak the stock set in 2021. In a nutshell, the pharma stock is down because sales of Comirnaty, the company’s COVID-19 vaccine, and Paxlovid, its antiviral COVID-19 treatment, evaporated much faster than expected.

Perhaps sensing a bargain, billionaires have been buying Pfizer with both hands. John Overdeck and David Siegel of Two Sigma Investments began a new position in the first quarter by acquiring 8.42 million shares. Daniel Sundheim at D1 Capital Partners also made a bold bet on Pfizer by purchasing 7.83 million shares for a new position.

Pfizer stock is up from its lowest point during the first quarter, but the pharmaceutical industry giant still offers a juicy 5.8% dividend yield at recent prices. Income-seeking investors will be glad to know the pharmaceutical giant has delivered annual payout raises since 2009.

Investors can expect Pfizer to announce another dividend raise this December. The company expects adjusted earnings to reach a range between $2.15 and $2.35 per share this year. That’s more than it needs to meet the annual dividend commitment currently set at $1.68 per share.

Pfizer shares have been trading for the low multiple of about 12.9 times the midpoint of management’s earnings expectation for 2024. At this low price, long-term investors can realize market-beating gains even if earnings creep forward at a snail’s pace.

In 2023, Pfizer spent $43 billion acquiring Seagen and its line of cancer therapies. Pfizer will probably report a significant earnings bump in the quarters ahead as it unwinds overlapping operations. Management predicts $4 billion in net cost savings by the end of 2024.

In addition to lowered expenses, Pfizer’s bottom line could benefit from soaring product sales. The company received a record nine new drug approvals from the Food and Drug Administration last year.

Lower expenses in the near term and new product launches that could drive growth over the next decade make this stock look like a bargain that is appropriate for most income-seeking investors.

2. Walgreens Boots Alliance

Decades of consecutive payout raises made Walgreens Boots Alliance (NASDAQ: WBA) one of the most reliable dividend stocks on Wall Street until it slashed its payout earlier this year, from $0.48 to $0.25 per share. The stock has fallen so far that it offers a 5.5% yield at recent prices.

Despite announcing a slashed payout this January, Walgreens attracted several billionaire investors in the first quarter, including the recently deceased Jim Simons. His firm, Renaissance Technologies, opened a new position with 1.83 million shares. Also in the first quarter, Jeff Yass increased Susquehanna’s position by 403% to 2.43 million shares.

Retail pharmacy is a low-growth industry at best. With increasing utilization of lower-cost online pharmacies, such as Mark Cuban’s Cost Plus Drugs, and profit margin pressure from pharmacy benefits management businesses, investors probably shouldn’t expect significant growth from Walgreens’ biggest operating segment.

Walgreens’ attempt to be more than a pharmacy chain and offer healthcare services has been a disaster. The company invested $5.2 billion in VillageMD in 2021, only to close 160 clinics this year and record a $5.8 billion impairment.

The retail pharmacy industry doesn’t seem like a smart place to put your money. Despite interest from billionaire investors, it’s probably best for the rest of us to avoid Walgreens stock until we see evidence that it can execute the vertical integration of a related business.

Should you invest $1,000 in Pfizer right now?

Before you buy stock in Pfizer, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $566,624!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of May 13, 2024

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.

Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead? was originally published by The Motley Fool

Read the full article here



Copyright © 2022 ONSWM News. Content posted on the Old North State Wealth News page was developed and produced by a third party news aggregation service. Old North State Wealth Management is not affiliated with the news aggregation service. The information presented is believed to be current. It should not be viewed as personalized investment advice. All expressions of opinion reflect the judgment of the authors on the date the articles were published. The information presented is not an offer to buy or sell, or a solicitation of any offer to buy or sell, any of the securities discussed.